Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists

Substituted [1,2,4]triazolo[4,3-alpha]quinoxalines as adenosine A2a receptor antagonists

US Patent 8435994 · Granted May 7, 2013

Estimated economic value: $67,103,000 ⓘ

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Clotting factor preparations for delivery into tissue of the intestinal tract us2025
PCSK9 antibody preparations for delivery into a lumen of the intestinal tract us2024
Pyridinone- and pyridazinone-based compounds and uses thereof2024
Clotting factor preparations for delivery into tissue of the intestinal tract us2023
Pharmaceutical compositions and methods for fabrication of solid masses comprisi2023
Biodegradable medical implants, polymer compositions and methods of use2023
Clotting factor preparations for delivery into tissue of the intestinal tract us2022
2,2-difluorodioxolo A2A receptor antagonists2021
Compounds inhibiting leucine-rich repeat kinase enzyme activity2021
Methods and articles for delivering viable cells into solid tissue2020
Substituted aminoquinazoline compounds as A2A antagonist2020
System and method for biphasic transdermal iontophoretic therapeutic agents2020